Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C.
Rona YaegerJared WeissMeredith S PelsterAlexander I SpiraMinal BarveSai-Hong I OuTiciana A LealTanios S Bekaii-SaabCloud P PaweletzGrace A HeaveyJames G ChristensenKaren VelasteguiThian KheohHirak Der-TorossianSamuel J KlempnerPublished in: The New England journal of medicine (2022)
Adagrasib had antitumor activity in heavily pretreated patients with metastatic colorectal cancer with mutant KRAS G12C, both as oral monotherapy and in combination with cetuximab. The median response duration was more than 6 months in the combination-therapy group. Reversible adverse events were common in the two groups. (Funded by Mirati Therapeutics; KRYSTAL-1 ClinicalTrials.gov number, NCT03785249.).